http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Advaxis Announces FDA Lifts Clinical Hold on Phase 1/2 Combination Study of Axalimogene Filolisbac with Durvalumab
-
Advaxis (ADXS) to Withdraw its Conditional MAA in EU for Axalimogene Filolisbac, Submitted IND to FDA for first ADXS-HOT Drug Candidate
-
Advaxis Provides Update on MAA Filing and ADXS-HOT Program
-
Advaxis Announces Dosing of First Patient with ADXS-NEO, an Investigational Customized Immunotherapy Approach Targeting Personal Neoantigens
-
Advaxis (ADXS) Reports Elimination of About 24% of Company’s Workforce as Part of Restructuring
-
Advaxis Announces Prioritization of Product Portfolio and Reports Fiscal 2018 Second Quarter Financial Results
-
Advaxis Appoints Molly Henderson as Chief Financial Officer
-
Advaxis (ADXS) Announced Prelim. Data from Ongoing Metastatic, Castration Resistant Prostate Cancer (mCRPC) Phase 1/2 KEYNOTE-046 Study, Conducted in Conjunction with Merck (MRK) Evaluating ADXS-PSA
-
Data Highlighting Advaxis’ ADXS-PSA Presented at ASCO Annual Meeting
-
Advaxis to Host Business Update and Second Quarter 2018 Financial Results Conference Call on June 7, 2018
-
Advaxis (ADXS) Says Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy
-
Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent
-
Advaxis Announces Executive Leadership Changes
-
Advaxis (ADXS) Says Preclinical Data Highlighting ADXS-Hot as Immunotherapy Presented in Poster Discussion at AACR
-
Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting
-
Advaxis (ADXS) Says Data Highlighting its ADXS-PSA Accepted as Poster Presentation
-
Data Highlighting Advaxis’ ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting
-
Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018
-
Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab)
-
Advaxis (ADXS) Submits Conditional MAA for Axalimogene Filolisbac for Second-Line Treatment of Metastatic Cervical Cancer in EU
-
Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union
-
Advaxis (ADXS) Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for Treatment of Recurrent Metastatic Cervical Cancer in International Journal of Gynecological Cancer
-
Advaxis Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic Cervical Cancer in the International Journal of Gynecological Cancer
-
Data Highlighting Advaxis’ Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies
-
Advaxis’ Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in International Journal of Radiation Oncology
-
Advaxis Reports Fiscal Year 2017 Financial Results and Provides a Business Update
-
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
-
Advaxis to Host Business Update and Fiscal Year End 2017 Financial Results Conference Call on December 21, 2017
-
Advaxis to Present at the Jefferies 2017 London Healthcare Conference
-
Advaxis to Receive $4.5 Million through the New Jersey Economic Development Authority NOL Program
-
Advaxis to Webcast Company Overview at the Cantor Fitzgerald Global Healthcare Conference
-
Two Abstracts Featuring Advaxis’ Lm-based Candidates Selected for Presentation at the 32nd Annual Society for Immunotherapy Cancer (SITC) Meeting
-
Advaxis to Present at Cantor Fitzgerald Global Healthcare Conference
-
Advaxis Reports Business Update and Third Quarter 2017 Results
-
Advaxis to Present at Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
-
Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders
-
Advaxis (ADXS) CEO, President and Board Member, Daniel O'Connor to Resign; Anthony Lombardo to Assume Interim CEO Role
-
Advaxis Announces Change in Leadership
-
Advaxis’ Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017
-
Advaxis to Present at 2017 BIO International Convention
-
Advaxis to Be Featured on Worldwide Business with kathy ireland®
-
Advaxis (ADXS) Offers Details on Registrational Trials, EU Regulatory and Commercial Plans
-
Advaxis Details Registrational Trials, EU Regulatory and Commercial Plans at Annual Investor & Analyst Day
-
Advaxis to Webcast Investor & Analyst Day 2017
-
Update: Webcast of Advaxis Presentation at Jefferies 2017 Global Healthcare Conference Now Available
-
Advaxis to Present at Jefferies 2017 Global Healthcare Conference
-
Synthetic Genomics Launches cGMP Suite for Pharmaceutical Quality Manufacturing of Synthetic DNA for Advaxis' Clinical Trials
-
Bristol-Myers Squibb (BMY) & Advaxis (ADXS) Report Clinical Collaboration to Evaluate ADXS-DUAL & Opdivo (Nivolumab) in Metastatic Cervical Cancer
-
Advaxis and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate ADXS-DUAL and Opdivo (nivolumab) in Metastatic Cervical Cancer
-
Advaxis to Host Investor & Analyst Day on June 12
